Intec Pharma - Bolstering the case for AP-CDLD
Intec Pharma recently released the results from two pharmacokinetic (PK) studies of AP-CDLD (n=18 and n=30). The data showed trends towards lower peak serum concentrations (Cmax) and a longer half-life (T1/2, although there was some inconsistency), which should reduce dyskinesia and off-time, respectively. Additionally, one study measured food effect, which was present but did not delay onset of effects, unlike the approved extended-release carbidopa/levodopa formulation, Rytary.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.